Scarica l'app Stockscreener
25.92
1.91%
0.33
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
Zimmer Biomet acquires rights to medical device for $140 million - Inside INdiana Business
Enterprise value to revenue forward of Pacira Biosciences, Inc. – BX:82P - TradingView
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare - TradingView
Pacira to divest iovera business to Zimmer Biomet in up to $140M deal - MSN
UnitedHealthcare adds separate reimbursement for Exparel By Investing.com - Investing.com Australia
Deals tracker: Banner Health to sell facility to Quorum Health - Modern Healthcare News
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal - Yahoo Finance
Pacira BioSciences to divest its iovera° business to Zimmer Biomet - Medical Buyer
Pacira BioSciences' Exparel Now Separately Reimbursed by UnitedHealthcare Across Outpatient Settings - marketscreener.com
PCRX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $38 - GuruFocus
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL® - The Manila Times
Zimmer Biomet to acquire iovera device from Pacira for $140m - Yahoo Finance
H.C. Wainwright Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Price to earnings forward of Pacira BioSciences, Inc. – NASDAQ:PCRX - TradingView
Pacira BioSciences (PCRX) Sells iovera° Business to Zimmer Biome - GuruFocus
Zimmer Biomet Holdings, Inc. agreed to acquire iovera ° Business of Pacira BioSciences from Pacira BioSciences, Inc. for $140 million. - marketscreener.com
Needham Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $32 - Moomoo
Pacira Biosciences Announces Agreement to Div - Moomoo
Zimmer to buy Pacira pain relief device for up to $140M - MedTech Dive
Pacira divests iovera device to Zimmer Biomet for up to $140m - Investing.com
Pacira Biosciences Announces Agreement To Divest Its Iovera° Business To Zimmer Biomet - TradingView
Pacira BioSciences stock rises on Zimmer Biomet deal By Investing.com - Investing.com South Africa
Pacira BioSciences stock rises on Zimmer Biomet deal - Investing.com UK
Pacira BioSciences Divests CryoTech to Zimmer Biomet - TipRanks
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet - The Manila Times
Pacira BioSciences Sells iovera° Device to Zimmer Biomet in $140 Million Deal, Focuses on Biopharma Innovation - Minichart
Pacira BioSciences to Divest iovera° to Zimmer Biomet for Up to $140 Million - Quiver Quantitative
Pacira BioSciences to Sell Iovera Cryoanalgesia Business to Zimmer for Up to $140 Million - TradingView
Pacira (NASDAQ: PCRX) divests iovera° business to Zimmer Biomet for up to $140M - Stock Titan
Pacira offloads iovera° for up to $140M, keeps spasticity program - Stock Titan
PCRX Forecast — Price Target — Prediction for 2027 - TradingView
Pacira Biosciences, Inc. Actuals & Estimates (NASDAQ:PCRX) - TradingView
Price to book forward of Pacira BioSciences, Inc. – NASDAQ:PCRX - TradingView
Enterprise value to EBIT forward of Pacira BioSciences, Inc. – NASDAQ:PCRX - TradingView
Enterprise value to EBIT forward of Pacira Biosciences, Inc. – FWB:82P - TradingView
Price to sales forward of Pacira BioSciences, Inc. – NASDAQ:PCRX - TradingView
Enterprise value to revenue forward of Pacira Biosciences, Inc. – FWB:82P - TradingView
Pacira BioSciences, Inc.(NasdaqGS: PCRX) added to Russell 2000 Value-Defensive Index - marketscreener.com
Pacira BioSciences, Inc.(NasdaqGS: PCRX) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Price to earnings forward of Pacira Biosciences, Inc. – FWB:82P - TradingView
Price to sales forward of Pacira Biosciences, Inc. – FWB:82P - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSci - The National Law Review
Pacira BioSciences (PCRX) Gains 3.6% as Stock Approaches Key Resistance ZoneSocial Sentiment - dars.gov.et
Pacira Biosciences, Inc. Actuals & Estimates (FWB:82P) - TradingView
Pacira Biosciences, Inc. Actuals & Estimates (SWB:82P) - TradingView
Pacira Biosciences Inc (PCRX) Institutional Confidence - TradingKey
Pacira Biosciences, Inc. Actuals & Estimates (GETTEX:82P) - TradingView
82P Forecast — Price Target — Prediction for 2027 - TradingView
Pacira Biosciences Inc (PCRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pacira BioSciences holds support above key levels, shares trade in a tight Nasdaq range - Ad-hoc-news.de
Pacira Biosciences Inc (PCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pacira Biosciences Inc (PCRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pacira Biosciences Inc (PCRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pacira Biosciences Inc (PCRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pacira Biosciences Inc (PCRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pacira Biosciences Inc (PCRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pacira Biosciences Inc (PCRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Precision Trading with Pacira Biosciences Inc. (PCRX) Risk Zones - Stock Traders Daily
Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and Rising Disease Burden | DelveInsight - GlobeNewswire Inc.
Insider Sell: Lauren Riker Sells Shares of Pacira BioSciences In - GuruFocus
Pacira BioSciences (PCRX) Slips 1.58% as Shares Test Support Near $21.84Hull Moving Average - dars.gov.et
0.17%
1.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):